Clinical Trials
7 trialsNCT00011414 2019-07-16
Phase I Trial of Tariquidar (XR9576) in Combination With Doxorubicin, Vinorelbine, or Docetaxel in Pediatric Patients With Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00082368 2017-08-17
PET Imaging With Tc-94m Sestamibi to Assess Resistance to Chemotherapy
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00069160 2012-10-12
Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00071058 2012-09-18
Surgery Plus Chemotherapy (Doxorubicin, Vincristine and Etoposide), Mitotane, and Tariquidar to Treat Adrenocortical Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00042302 2012-05-23
A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Paclitaxel/Carboplatin as First-Line Therapy in Non-Small Cell Lung Cancer (NSCLC)
QLT Inc.
Phase 3 Terminated
NCT00042315 2012-05-23
A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Vinorelbine as First-Line Therapy in Non-Small Cell Lung Cancer (NSCLC)
QLT Inc.
Phase 3 Terminated
NCT00001944 2008-03-04
Vinorelbine and XR9576 to Treat Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Completed